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Intracellular CD24 disrupts the ARF–NPM
interaction and enables mutational and viral
oncogene-mediated p53 inactivation
Lizhong Wang1,*, Runhua Liu1,*, Peiying Ye2, Chunshu Wong2,3, Guo-Yun Chen2, Penghui Zhou4, Kaoru Sakabe2,
Xincheng Zheng5, Wei Wu5, Peng Zhang6, Taijiao Jiang6, Michael F. Bassetti7, Sandro Jube2, Yi Sun7,
Yanping Zhang8, Pan Zheng2 & Yang Liu2

CD24 is overexpressed in nearly 70% human cancers, whereas TP53 is the most frequently
mutated tumour-suppressor gene that functions in a context-dependent manner. Here we
show that both targeted mutation and short hairpin RNA (shRNA) silencing of CD24 retard
the growth, progression and metastasis of prostate cancer. CD24 competitively inhibits ARF
binding to NPM, resulting in decreased ARF, increase MDM2 and decrease levels of p53 and
the p53 target p21/CDKN1A. CD24 silencing prevents functional inactivation of p53 by both
somatic mutation and viral oncogenes, including the SV40 large T antigen and human
papilloma virus 16 E6-antigen. In support of the functional interaction between CD24 and
p53, in silico analyses reveal that TP53 mutates at a higher rate among glioma and prostate
cancer samples with higher CD24 mRNA levels. These data provide a general mechanism for
functional inactivation of ARF and reveal an important cellular context for genetic and viral
inactivation of TP53.
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D24 is a glycosyl-phosphatidyl-inositol (GPI)-anchored
cell surface molecule. Although found in many tissues,
CD24 is most abundant in haematopoietic and immature
neuronal cells1. Accumulating data have demonstrated that CD24
is among the most overexpressed protein in cancer cells2 and is a
valuable marker indicative of poor prognosis for cancer patients,
such as those with non-small-cell lung cancer3, colon cancer4,
oesophageal squamous cell carcinoma5, hepatocellular
carcinoma6, ovarian7, breast8, glioma9,10 and prostate11 cancers.
The role of CD24 in tumour cell growth has been demonstrated
by ectopic and/or inducible expression12,13, targeted mutation14,
gene silencing12 and antibody blocking15. By localizing to
caveolae, CD24 associates with Src family members, such as
Src, Lck and Lyn16–19, linking CD24 to activation of intracellular
signal transduction cascades. In addition, cell surface CD24 is
often implicated in tumour metastasis19–23, as fucosylated CD24
interacts with P- and E-selectin, mediating rolling along the
endothelium and allowing invasion of tumour cells to distal
sites24–26.
Biogenesis of cell surface proteins involves elongation arrest
caused by interaction of the signal peptide with the signal
recognition protein. This pause occurs normally when the
nascent chain reaches an average of 70 amino acids27. As CD24
has an open-reading frame of 76 or 80 amino acids in mouse
and human, respectively28,29, translation of CD24 may have
occurred before translocation to the endoplasmic reticulum.
Thus, unless degraded, a signiﬁcant population of CD24 may
reside intracellularly, by default. In addition, intracellular CD24
may accumulate in cancer samples because of widespread
disruption of genes involved in the processing of GPI-anchored
molecules30. For example, in colon cancer, intracellular CD24 is
associated with cancer prognosis4. The signiﬁcance and
mechanism of intracellular CD24 in tumour progression has
not been studied.
The p19Arf(p14ARF)/p16INK4a locus is unique in cancer
biology as it encodes two potential tumour-suppressor genes
by using different open-reading frames and a distinct exon 1
(ref. 31). ARF and p16 act through the p53 and Rb pathways,
respectively32–35. ARF promotes p53 function by inactivating
MDM2 (ref. 33), the E3 ligase that ubiquitinates p53 and targets it
for degradation36. The signiﬁcance of the individual gene
products in human tumorigenesis is unclear as selective genetic
inactivation of either ARF or INK4a is rare in human cancer
samples37. Given the strong cancer phenotype in mice with
selective inactivation of Arf (ref. 32), it is surprising that genetic
inactivation of p14ARF alone rarely occurs in human cancer37.
The scarcity of mutations in p14ARF has roused scepticism of the
signiﬁcance of ARF as a tumour suppressor37. However, it is also
possible that other mechanisms are responsible for ARF
inactivation. In this context, it is of note that the nucleolar
protein NPM/B23 interacts with ARF and protects it from
degradation38.
TP53 is the most frequently mutated tumour-suppressor
gene39. Unlike APC, another frequently mutated tumour
suppressor in intestinal cancer40, most TP53 mutations are
missense and thus allow production of full-length mutant p53
proteins39. Perhaps due to reduced expression of the p53 target
gene MDM2, mutant p53 often accumulates at higher levels41.
Although most TP53 mutations are presumed loss-of-function,
some p53 mutants have oncogenic function42,43, whereas others
exhibit a temperature-sensitive phenotype44. Understanding the
cellular context of p53 mutant function may help restore its
tumour-suppressor function while disabling its oncogenic
activity. Here we provide a missing link between CD24
overexpression and functional inactivation of the tumoursuppressor genes TP53 and ARF.
2

Results
Cd24 deletion retards development of prostate cancer. To test
Cd24 function in a spontaneous cancer model, we crossed the
Cd24-null allele45 into TRAMP mice, a transgenic model that
develops spontaneous prostate adenocarcinoma due to the
expression of the SV40 T antigen under control of the rat
probasin promoter46. As shown in Fig. 1a, the onset of palpable
tumour development in the prostate of TRAMP mice was
signiﬁcantly delayed by deletion of either one or two alleles of the
Cd24 gene. When the prostate size was measured at 30 weeks by
magnetic resonance imaging (MRI), the prostate volume was
signiﬁcantly reduced in a gene dose-dependent manner
(P ¼ 0.0026, analysis of variance trend test; Fig. 1b,c). At 35
weeks, the mice were killed and their prostates were weighted.
CD24 deﬁciency also decreased the prostate weight at 35 weeks
(Fig. 1d). As shown in Fig. 1e and Supplementary Fig. 1 and
summarized in Fig. 1f, the majority of cancer in wild-type (WT)
TRAMP mice had progressed to poorly differentiated
adenocarcinomas (7/12) and distal metastases (8/12) into
the kidneys, lungs and liver. In contrast, only 1 mouse in
the Cd24  /  (1/9) and Cd24 þ /  (1/12) cohorts developed
poorly differentiated adenocarcinomas, whereas 1/12 Cd24 þ / 
and 0/9 Cd24  /  mice had metastasis. Therefore, in addition to
reduced tumour size, inactivation of a single allele of Cd24
signiﬁcantly reduced the malignancy of the tumours.
Cd24-deﬁcient mice have a normal prostate morphology
(Supplementary Fig. 2) with comparable numbers of luminal
and basal epithelial cells (Supplementary Fig. 3a) and prostate
weights (Supplementary Fig. 3b). In addition, SV40 T antigen was
expressed in both normal and malignant cells of the CD24deﬁcient prostate in TRAMP mice (Supplementary Fig. 4a),
consistent with normal expression of probasin (Supplementary
Fig. 4b), the promoter used to drive expression of SV40 T antigen.
These data suggest that the reduction in prostate cancer incidence
was not due to a lack of SV40-expressing cells.
Probing Oncomine.com database revealed that CD24 mRNA
is overexpressed in prostate cancer tissues (Fig. 2a). In the
TRAMP model, Cd24 was expressed in cancer cells but not
in the normal prostate gland (Fig. 2b). Heterozygous deletion of
Cd24 resulted in a quantitative reduction of Cd24 protein
(Fig. 2c). As Cd24 is highly expressed in haematopoietic cells
and plays important roles in both adaptive and innate immunity,
we sought to determine whether the Cd24 status in the
haematopoietic cells contributes to tumorigenicity. To achieve
this goal, we lethally irradiated Cd24 þ / þ TRAMP mice and
transplanted them with bone marrow from either Cd24  /  or
Cd24 þ / þ mice (Fig. 2d). Tumour development in the prostate
was measured by MRI at 30 weeks and conﬁrmed by histology.
In the chimera mice, all leukocytes expressed Cd24 according to
the genotype of donor cells (Fig. 2e), conﬁrming complete
replacement of the haematopoietic system. However, in two
independent experiments, the genotype of bone marrow-derived
cells had no impact on prostate size (Fig. 2f). Thus,
prostate tumorigenesis was independent of Cd24 status in the
haematopoietic cells.
Intracellular CD24 promotes growth of cancer cells. As the ﬁrst
step to assess the function of CD24 in the growth of human
prostate cancer cell lines, we analysed the expression of CD24
mRNA and protein from three cell lines, DU145, LNCaP and
PC3. As shown in Fig. 3a, DU145 expressed the highest levels of
CD24 mRNA, whereas LNCaP did not express detectable levels.
A moderate level of CD24 mRNA was observed in the PC3 cell
line. To determine the function of CD24 in DU145 proliferation,
we used two independent shRNAs to silence CD24 expression.
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Figure 1 | Cd24 promotes onset and progression of prostate cancer in TRAMP mice. (a) Onset of palpable prostate tumour development in Cd24 þ / þ ,
Cd24 þ /  and Cd24  /  TRAMP mice was observed over 35 weeks. P-value of log-rank tests are Cd24 WT versus Cd24 þ /  , P ¼ 0.0001; Cd24 WT
versus Cd24  /  , P ¼ 0.0017; Cd24 þ /  versus Cd24  /  , P ¼ 0.51. (b) Representative images of prostates from 30-week-old Cd24 þ / þ (n ¼ 7),
Cd24 þ /  (n ¼ 11) and Cd24  /  (n ¼ 9) TRAMP mice. (c) Prostate sizes in 30-week-old TRAMP mice in Cd24 þ / þ , Cd24 þ /  and Cd24  /  TRAMP
mice. The lower abdominal area was divided into 0.4-mm-thick slices and MRI images were acquired to provide continuous images of the whole prostate.
The surface area of the prostate slices was traced by segmenting and summed to estimate the total volume. Analysis of variance (ANOVA) tests revealed
an extremely signiﬁcant Cd24 gene dose effect on the prostate size (P ¼ 0.00026). (d) The weights of 35-week-old Cd24 þ / þ (n ¼ 9), Cd24 þ /  (n ¼ 22)
and Cd24  /  (n ¼ 10) TRAMP prostates. ANOVA tests revealed an extremely signiﬁcant Cd24 gene-dose effect on the prostate weight (P ¼ 0.00011).
(e) Representative histology of prostate carcinomas (PCa) that developed in Cd24 þ / þ Cd24 þ /  , and Cd24  /  TRAMP mice. The data show a
difference in the degree of differentiation in tumour morphology. (f) Cd24 promotes progression (left panel) and metastasis (right panel) of prostate
cancer in the TRAMP model. The prostate tissue was examined double blind and classiﬁed into the following categories: normal prostate, hyperplasia
prostate (HP), intraepithelial neoplasia in the prostate (PIN), moderate (mod) to well-differentiated (well diff) PCa and poorly differentiated PCa. Cancer
was scored metastatic if one or more distal metastases to either the lungs, kidneys or liver were detected histologically. Examples of tumours at each
grade are shown in e, whereas that of normal prostate and hyperplasia are shown in Supplementary Fig. 1. Pearson’s w2 test was used to determine whether
the Cd24 geneotypes affected the progression to poorly differentiated PCa (left panel) or distal metastasis (right panel).

As shown in Fig. 3b,c, both shRNAs reduced CD24 mRNA levels
by approximately fourfold and CD24 protein levels to barely
detectable levels. In both 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (Fig. 3d) and colony formation
(Fig. 3e) assays, a signiﬁcant reduction in DU145 growth was
observed after silencing CD24. Consistent with this observation,
the growth rates of the DU145 tumour in immunodeﬁcient Il2Rg  /  Nod.Scid (NSG) mice (Fig. 3f) and nu/nu
mice (Supplementary Fig. 5) were substantially reduced (Fig. 3f).
The role for CD24 in tumour growth is further substantiated by a
signiﬁcant reduction in terminal tumour weight (Fig. 3g).

To understand the molecular mechanism by which CD24
silencing causes growth suppression, we compared the gene
expression proﬁles of scrambled, non-silenced control (Scr)
versus CD24 shRNA-silenced DU145 cells by gene array analysis.
Using Po0.001 and less than 66% or greater than 150% of
control levels as a cutoff, we found that as a result of CD24 gene
silencing, 408 genes were downregulated, whereas 618 genes were
upregulated (Fig. 4a and Supplementary Data set 1). The top ten
pathways affected are listed in Supplementary Table 1. Among
them, the most signiﬁcantly affected pathway was cell cycle
regulation (P ¼ 2  10  5). For example, the CDKN1A mRNA,
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Figure 2 | Cd24 in non-haematopoietic cells contributes to tumour growth. (a) Overexpression of CD24 mRNA in human prostate cancer tissue based on
analysis of two data cohort deposited in Oncomine.com. Two reported cohorts with a sufﬁcient number of matched cancer and normal tissue were
analysed. P-values were calculated by Student’s t-tests69,70. (b) Expression of Cd24 in Cd24 þ / þ PCa but not Cd24  /  PCa or normal Cd24 þ / þ prostate
epithelia. Data shown are representative images and have been reproduced three times. (c) Cd24 levels in TRAMP prostate are gene-dose dependent. Agematched Cd24 þ / þ and Cd24 þ /  prostate were analysed for Cd24 levels by western blot. (d) Diagram of experimental design. Eight-week-old Cd24 þ / þ
TRAMP mice were lethally irradiated and transplanted with 5  106 bone marrow cells at 1 day after irradiation. The prostate size was measured by MRI at
30 weeks of age. (e) Successful replacement of haematopoietic cells from the donor bone marrow based on Cd24 expression. (f) Means and s.d. of the
prostate volume in the bone marrow chimera mice.

which encodes p21, was signiﬁcantly elevated (Fig. 4b). This
increase in p21 corresponded with elevated levels of p53 protein
(Fig. 4c). Given the function of p21/CDKN1A in G1 arrest, we
evaluated the role of CD24 in cell entry into S phase and beyond.
We starved DU145 cells under serum-free conditions for 48 h,
which arrested the cells at the G0-G1 phase. After 24 h of serum
stimulation, more than 70% of the scrambled shRNA-transduced
DU145 cells were at either S or G2-M phases (Fig. 4d). In
contrast, only 39–49% of the CD24 shRNA-transduced cells
entered S or G2-M phases (Fig. 4d). Therefore, CD24 contributes
to cell re-entry into cell cycle following starvation. To determine
whether CD24 overexpression is sufﬁcient to promote tumour
cell growth, we ectopically expressed CD24 in the LNCaP cell line
that does not express CD24. As shown in Fig. 4e, CD24
expression reduced p53 and p21 without marked effect on p27.
Consistent with reduced expression of tumour-suppressor genes,
CD24 increased LNCaP cell proliferation (Fig. 4f).
Interestingly, cell surface staining by ﬂow cytometry revealed
that only DU145 cells expressed cell surface CD24 (Fig. 5a). To
determine whether CD24 is expressed intracellularly, we ﬁxed the
cells with 4% paraformaldehyde and permeabilized them with
detergent to allow antibody access to intracellular CD24. As
shown in Fig. 5a, permeabilization increased the levels of CD24
detected in a cell by an average of ﬁvefold in DU145 cells. Thus,
the majority of CD24 must reside intracellularly. To determine
whether CD24 resides in the cytoplasm or in the nucleus, we
compared the amount of CD24 in 0.1% NP-40 soluble
(cytoplasmic and plasma membrane) and insoluble (putatively
nuclear) fractions. The 0.1% NP-40 insoluble fraction was
4

incubated in 3 mM EDTA and 0.2 mM EGTA to isolate the
nucleoplasm. CD24 was detected in both cytoplasmic and nuclear
fractions (Fig. 5b). As membrane-bound GPI-anchored molecules
may be insoluble because of its association with caveolae47, we
used confocal microscopy to conﬁrm the intracellular distribution
of CD24 relative to that of microtubules and DNA. We observed
increased CD24 levels and alterations in CD24 distribution
during mitosis. As shown in Fig. 5c and Supplementary Fig. 6,
compared with interphase, increased levels of CD24 were found
in prophase and metaphase. Also during metaphase, CD24
seemed to distribute itself more evenly with less staining of CD24
in the membrane and more staining in the cytoplasm. This shift
was reversed as the cells entered telophase. To conﬁrm the
increase in CD24 levels, we arrested DU145 cells at G2 using
nocodazole and assessed CD24 protein levels at different time
points following nocodazole removal. Concomitant with an
increase in Cyclin B1, a marked increase of CD24 was observed
as early as 30 min after removal of nocodazole. The increase was
transient and largely disappeared at 2 h after nocodazole removal
(Fig. 5d).
Next, we tagged CD24 at the C- and N-termini to study its
localization (Fig. 5e). Interestingly, tagging CD24 at the
C-terminus prevented its localization to the cell surface, whereas
tagging the N-terminus of mature CD24 protein resulted in
plasma membrane and intracellular localization, as shown in
Fig. 5f. The intracellular distribution of CD24-GFP (C) was
conﬁrmed by staining non-permeabilized cells with an anti-CD24
monoclonal antibody (Fig. 5g). Moreover, CD24 was expressed
as GFP fusion proteins, as they reacted with both anti-GFP and
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Figure 3 | CD24 promotes growth of DU145 cells. (a) CD24 mRNA levels in three human prostate cancer cell lines are displaced as % of glyceraldehyde
3-phosphate dehydrogenase (GAPDH). (b) Efﬁcient gene silencing of the CD24 gene based on the protein (insert, representative images that have been
reproduced three times) and RNA levels. (c) ShRNA silencing eliminates cell surface CD24 expression as determined by ﬂow cytometry. Data shown are
representative proﬁles and have been reproduced three times. (d) ShRNA silencing of CD24 reduces the growth rate as measured by the 3-(4,5dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide assay. Means and s.d. of the relative cell proliferation are shown on the given days. The study has
been reproduced three times. (e) Reduced growth rate of tumour cells based on colony size. Data shown are representative images and have been
reproduced three times. (f) ShRNA silencing of CD24 reduced the tumour growth in the Il2rg  /  NOD.SCID (NSG) mice. The mice received a
subcutaneous injection of 5  106 tumour cells. Data shown are means and s.d. of the tumour volumes. (g) Weights of tumours at day 39. Error bars,
s.d. Scr n ¼ 14, Sh1, n ¼ 9, Sh2 n ¼ 9 for f and g. Substantially similar data were obtained when the cells were injected into nu/nu mice.

anti-CD24 antibodies by western blot analysis (Fig. 5h). Notably,
CD24-GFP (N) was considerably more heterogeneous than
CD24-GFP (C), reﬂecting its heterogeneous glycosylation status
compared with CD24-GFP (C). To determine whether the
intracellular form was sufﬁcient to promote tumour cell growth,
we used genetic complementation to conﬁrm that the impact of
gene silencing was attributable to CD24. We reconstituted CD24silenced DU145 cells with either CD24-GFP (C) or GFP-CD24
(N) and monitored the impact of CD24 on tumour cell
proliferation in vitro. As shown in Fig. 5i, the intracellular form
of CD24, CD24-GFP (C), was at least as potent as CD24-GFP (N)
in promoting tumour cell growth. CD24 silencing also reduced
the growth of PC3 cells (Supplementary Fig. 7). As CD24 is
expressed only intracellularly in PC3 cells, its contribution to PC3
growth suggests that intracellular CD24 is sufﬁcient to promote
cancer cell proliferation. Taken together, the data presented in
this section demonstrate that intracellular CD24 is sufﬁcient to
promote tumour cell proliferation.
CD24 competes with ARF for binding to NPM. In order to
understand how CD24 encourages cancer cell growth, we identiﬁed CD24-associated proteins by mass spectrometric analysis of
trypsin-digested anti-CD24 immunoprecipitates from WT but
not CD24-deﬁcient spleen cells48. We identiﬁed 12 unique NPM
peptides in immunoprecipitates from Cd24 þ / þ spleen cells and
none from Cd24  /  spleen cells (Supplementary Table 2). These
data suggest that CD24 may interact with NPM. NPM is a
nucleolar protein and forms a punctate structure in the nucleus

that dispersed during mitosis. Interestingly, the CD24–NPM
association occurred transiently during mitosis. CD24 was more
broadly distributed than NPM at the interphase (Fig. 6a),
although some overlap between the two signals can also be
observed (Fig. 6b). However, at metaphase and anaphase, CD24
and NPM were largely co-localized (Fig. 6a,b; see also
Supplementary Fig. 8 for single-colour images). To conﬁrm this
observation in human tumour cells, we immunoprecipitated
CD24 from DU145 cells and probed them with an anti-NPM
monoclonal antibody. As shown in Fig. 6c, anti-CD24 coprecipitated NPM. Conversely, anti-NPM co-precipitated CD24.
To map the region in NPM that interacts with CD24, we used a
series of Myc-tagged deletion mutants of NPM and HA-tagged
CD24. As shown in Fig. 6d, full-length (1–294) and all but
one (AA1-177) truncation mutant co-precipitated CD24. As a
small NPM C-terminal only fragment encompassing AA196-294
co-precipitated CD24, CD24 interacts with the C-terminus
of NPM. However, as the AA196-294 fragment showed
reduced association compared with the AA117-294 fragment, a
contribution of the NPM core region to the interaction cannot be
ruled out.
CD24 alleviates tumour-suppressor activity of p14ARF. To
determine whether CD24 competes with ARF for interaction with
NPM, we co-incubated recombinant ARF with either control
glutathione S-transferase (GST) or NPM–GST in the presence of
increasing amounts of CD24-Fc or control IgG-Fc. The proteins
that associated with the GST-fusion proteins were pulled down
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Figure 4 | CD24 reduces levels of p53 and p21 and promotes tumour cell proliferation. (a) Heat-map depiction of alterations in gene expression in
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using glutathione beads and identiﬁed by western blot using antiNPM, anti-CD24 or anti-ARF. As shown in Fig. 7a, CD24-Fc, but
not control IgG-Fc, blocked the ARF–NPM association in a dosedependent manner. To determine whether CD24 inhibits the
ARF–NPM association in cancer cells, we used a proximity
ligation assay to assess the association between NPM and ARF in
DU145 cells with or without CD24 silencing. A summary of three
experiments is shown in Fig. 7b, whereas representative images
from one experiment are shown in Fig. 7c. These data demonstrate that shRNA silencing of CD24 increased the NPM–ARF
association in tumour cells. To test if CD24 also affects the ARF–
NPM interaction in normal cells, we compared the amounts of
Npm-associated Arf in WT and Cd24  /  thymocytes. As shown
in Fig. 7d, a substantial increase in Npm-associated Arf was
observed in Cd24  /  thymocytes. These results demonstrate
that CD24 inhibited ARF association with NPM.
As NPM enhances ARF stability, we next tested if shRNA
silencing of the CD24 gene increases ARF stability and
accumulation using G2-M-arrested DU145 cells. In order to
observe CD24-dependent changes on steady-state levels of
ARF without the inﬂux of new protein synthesis, we treated
G2-M-arrested cells with cycloheximide (CHX) and measured
ARF levels at 0, 2 and 4 h after CHX treatment. As shown in
Fig. 7e,f, in comparison to Scr shRNA-transfected cells, CD24
6

shRNA-transfected cells markedly increased ARF protein levels at
time 0. Moreover, although ARF was clearly detectable at 4 h after
CHX treatment in CD24-silenced DU145 cells, very little (if any)
ARF was detected in Scr shRNA-transduced control cells 2 h after
CHX treatment.
Chen et al.49 reported that the ARF–NPM interaction in the
nucleolus prevented ULF-mediated ARF degradation in the
nucleoplasm. We compared ULF levels in DU145 cells with or
without CD24 silencing and found that ULF was unaffected by
CD24 silencing (Fig. 7g). Therefore, CD24 regulated ARF levels
by reducing NPM–ARF association rather than through
increasing the levels of the ubiquitin ligase ULF.
To determine whether CD24 promotes tumour cell growth by
antagonizing ARF function, we introduced ARF and/or CD24
into the ARF-deﬁcient U2OS cell line50. As shown in Fig. 7h,
ectopic expression of CD24 reduced ARF levels. More
importantly, CD24 bypassed ARF-mediated growth inhibition
but had no effect in ARF-null cells (Fig. 7i). Therefore, CD24
promotes tumour growth by antagonizing ARF function.
ShRNA silencing of CD24 restores mutant p53 function.
Given the effect of ARF on MDM2 and its substrate p53, we
evaluated if CD24 affected the expression of MDM2 and p53 in
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total cellular CD24 (bottom). (b) Analysis of CD24 in the cytoplasmic and plasma membrane fraction (Cp þ Cm), nucleoplasm (Np) and the insoluble
fraction that includes chromatin by western blot. The efﬁciency of the fractionation was monitored by the presence of b-actin (Cp þ Cm þ Np), Lamin (Np)
and H1.5 (chromatin). (c) Confocal microscopy reveals dynamic upregulation and localization of CD24 during mitosis. Note alterations of CD24 distribution
and signal intensity at different phases during mitosis. See Supplementary Fig. 6 for single-colour images. (d) Upregulation of CD24 during mitosis as
revealed by western blot of cellular lysates prepared from nocodazale-synchronized DU145 cells. (e) Diagram of CD24-GFP and GFP-CD24 constructs. The
N-terminus-tagged CD24 was produced by inserting the GFP-coding sequence after the signal peptide, whereas the C-terminus-tagged CD24 was
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an ARF-dependent manner. As shown in Fig. 8a, in ARFexpressing DU145 cells, CD24 silencing increased the levels of
ARF and p53 and reduced that of MDM2. Elevated ARF levels
contributed to CD24-mediated reduction of MDM2 and p53 as
CD24 had no effect on the levels of MDM2 and p53 in ARFdeﬁcient U2OS cells (Fig. 8b). Furthermore, expression of p21
following shRNA silencing of CD24 was due to elevated p53 levels
as shRNA silencing of p53 in DU145 cells substantially reduced
p21 levels (Fig. 8c).
DU145 cells harbour a bi-allelic missense mutation of
TP53 (ref. 51; (p53223L and p53274F). Both mutants exhibit
tumour-suppressor activity based on the cellular context and
culture conditions52,53. As the molecular basis of this contextdependent tumour-suppressor activity is unknown, we tested
whether CD24 determines the function of the mutant p53. We
used two luciferase reporter constructs driven by the p21
promoter with a p53 consensus binding site (wt/WWP-luc) or
without a p53-binding site (mu/DW-luc)54. The p53-dependent

activity was further evaluated by transfection of an shRNAtargeting endogenous p53. As shown in Fig. 8d, in CD24expressing DU145 cells, no endogenous p53 activity was detected,
as basal levels of p21 promoter activity were observed regardless
of a p53-binding site or p53 silencing. In contrast, shRNA
silencing of CD24 resulted in a dramatic increase in p21 promoter
activity. The activity was entirely dependent on (i) the p53binding site and (ii) the endogenous p53 protein itself, as an
induction was not observed in the luciferase reporter driven by
the p21 promoter with the p53 site deleted (mut) or was
abrogated upon transfection of a p53-targeting shRNA (Fig. 8d).
Thus, upregulation of p53 induced by CD24 silencing was
causally related to increased p21 expression in DU145 cells.
To determine the functional impact of CD24 on commonly
occurring cancer-associated p53 mutants, we ectopically
expressed TP53 mutants in the DU145 cell line that had been
depleted of endogenous p53, using a p53 shRNA speciﬁc for
endogenous TP53 via 30 untranslated region (UTR) targeting,
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thus sparing the mutant TP53 cDNA (complementary DNA)
lacking the 30 UTR. As expected, CD24 silencing increased
accumulation of mutant p53 protein (Fig. 8e). The function
of the TP53 mutants was measured based on transactivation of
the p21 promoter with or without a p53-binding site. As
expected, in the absence of exogenous TP53 cDNA, the luciferase
activity of both promoters was unaffected by mutation of the
p53-binding sites, regardless of whether the endogenous CD24
gene was silenced (Fig. 8f). These data show effective silencing
of the endogenous TP53. Surprisingly, shRNA silencing of
CD24 increased activities of WT as well as three of the four
TP53 mutants, including the p53R273H mutant, the most
common TP53 mutation, and p53V143A and p53R280T. The other
common mutant, p53R175H, which causes a conformational
change in p53, remained inactive regardless of CD24 status
(Fig. 8f).
Consistent with the reporter assays, silencing CD24 allowed
signiﬁcant induction of p21 mRNA by p53R273H, p53V143A and
p53R280T, but not p53R175H (Fig. 8g). Interestingly, the impact of
CD24 was not uniform to all p53 target genes. As shown in
Fig. 8f, with the exception of a moderate effect of p53R273H, none
of the TP53 mutants tested signiﬁcantly induced expression of the
8

endogenous MDM2 gene. The lack of MDM2 induction explains
the increased accumulation of functional p53 mutant protein
after CD24 silencing (Fig. 8a). Although the mechanism for
selective induction of p21 by the p53 mutant remains to be
elucidated, selective induction of p21 has been reported in
tumour cells after high doses of irradiation or undergoing
chemotherapy55,56.
Cd24 silencing bypasses p53 inactivation by viral oncogenes.
p53 protein is inactivated by SV40 T antigen and this inactivation
requires interaction between p53 and SV40 T antigen57. To
determine whether Cd24 abrogates p53 function in SV40 T
antigen-induced cancer cells, we compared the SV40 TAgtransduced mouse prostate cancer cell line C3 with or without
endogenous Cd24 expression. As shown in Fig. 9a, shRNA
silencing of Cd24 resulted in increased p53 levels, as expected. To
determine whether the increased p53 was subjected to
inactivation by SV40 T antigen, we assessed the relative amount
of SV40 T antigen-associated versus non-associated p53 in Cd24expressing and non-expressing C3 cells. As shown in Fig. 9a, right
panels, Cd24 shRNA silencing resulted in a massive increase of
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Figure 7 | CD24 inhibits tumour-suppressor activity of ARF by antagonizing the NPM–ARF interaction. (a) Recombinant CD24 associates with
recombinant NPM and blocks the ARF–NPM interaction. Control GST and NPM–GST fusion proteins were incubated with indicated amounts of CD24-Fc
and/or ARF. The GST or GST–NPM1-associated proteins were determined by western blot after pull-down with glutathione beads. (b,c) Proximity
ligation assay reveals CD24 antagonism of NPM–ARF association. Scrambled or CD24 shRNA-transduced DU145 cells were compared for endogenous
NPM–ARF association. Images were obtained using an Olympus BX61 microscope using a  60 oil objective. Scale bar, 50 mm. Image J software was used
to quantify ﬂuorescent intensities. Mean ﬂuorescent intensities were determined from more than 100 cells per slide. This experiment has been repeated
three times. Data shown are means and s.d. of three independent repeats (b) and representative images (c). (d) Cd24 reduces Npm-associated p19Arf.
Spleen lysates from WT and Cd24  /  mice were precipitated with anti-Npm mAb. The amounts of Npm and p19Arf in the immunoprecipitates were
determined by western blot. IgG heavy chain (IgHC) was used as loading controls. (e) Regulation of ARF levels and stability by endogenous CD24.
Scrambled or shRNA-silenced DU145 cells were arrested at G2/M phase overnight and then treated with CHX for 0, 2 and 4 h. The levels of CD24 (upper
panel) and p14ARF were analysed by western blot. (f) Decay kinetics of p14ARF are shown as % of ARF protein at different times after CHX treatment.
(g) ShRNA silencing of CD24 does not affect the levels of the ARF E3 ligase ULF. (h) Ectopic expression of CD24 reduces ARF levels. U2OS cells that
ectopically expressed CD24 alone, ARF alone or both were analysed for their CD24 and ARF levels by western blot. (i) CD24 expression alleviates ARF
tumour-suppressor activity. Data shown are growth kinetics of U2OS cells transfected with the given plasmids. Data shown are means and s.d. of cell
numbers during the 6-day period. All data in this ﬁgure have been reproduced two or three times.

SV40 T antigen-free p53, although a small increase in SV40 T
antigen-associated p53 was also observed. As CD24 was not coprecipitated with SV40 T antigen, it is likely that the primary
function of CD24 is to decrease p53 levels. Consistent with
inactivation of p53 by large T antigen in CD24-expressing C3
cells, the p21 promoter was largely inactive in the scrambled
shRNA-transduced C3 cells (Fig. 9b, top panel). Importantly,
shRNA silencing of Cd24 caused a major increase in p21
promoter activity (Fig. 9b, top panel). This increase was fully
attributable to p53 as it required a p53-binding site on the p21
promoter and was abrogated by shRNA silencing of TP53
(Fig. 9b, top panel). We compared the levels of p21 and p53 in
prostate cancer from Cd24 þ / þ , Cd24 þ /  and Cd24  / 
TRAMP mice by immunohistochemistry (IHC). The tumour
cells in this model have WT TP53 (ref. 58). As shown in Fig. 9c,

Cd24 þ /  and Cd24  /  prostate cancers showed considerably
higher levels of p53 and p21 than the WT prostate cancer.
Human papilloma viruses (HPVs) 16 and 18 are now
well-established causes for human cancer59,60. It has been
demonstrated that the viral E6 oncogenes associates with p53
to inactivate its tumour-suppressor activity61. To determine
whether CD24 is required for E6-mediated p53 inactivation, we
transduced HPV16 E6 gene into the C3 cell line (C3-E6),
and compared the levels of p53 in Scr or Cd24 shRNA-silenced
C3-E6 cells. As shown in Fig. 9d, Cd24-silencing increased
p53 levels in the C3-E6 cells. Importantly, most of the increased
p53 was not associated with E6 (Fig. 9d). Corresponding
to increased E6-unbound p53, a signiﬁcant increase in p21
promoter activity was observed after CD24 silencing (Fig. 9b,
lower panel).
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CD24 silencing reactivates mutant p53. We tested the effect of
WT and mutant p53 for their inhibition of proliferation of Scr or
CD24 shRNA-transduced DU145 cells. Endogenous p53 was
removed by an shRNA targeting the 30 UTR of the TP53 gene.
The cDNAs for WT and mutant p53 (lacking 30 UTR) were
introduced into either Scr or CD24 shRNA viral vector-transduced cell lines. WT p53 suppressed growth of DU145 regardless
of CD24 expression. In the Scr shRNA transfectants, none of the
mutants greatly reduced the colony number or size, as expected.
A general but moderate reduction in colony numbers by all
mutants was observed, which is likely due to more efﬁcient
expression of the drug-resistance gene in the vector devoid of p53
insert. In CD24-silenced DU145 cells, however, p53R273H was
almost as efﬁcient as WT p53 in suppressing colony formation.
The p53V143A and p53R280T mutants were also signiﬁcantly more
efﬁcient in suppressing proliferation of cells that were silenced of
the CD24 gene, although CD24 silencing did not confer tumoursuppressor activity to p53R175H.
10

The above data suggested that for a high proportion of p53
mutations, CD24 expression may be a necessary co-factor in
cancer development. To explore this possibility, we searched
the Cancer Genome Atlas (TCGA) database for a possible
association between CD24 overexpression and TP53 mutation in
cancer samples. We limited our search to cohorts that meet two
criteria. First, both RNAseq and p53 status data are available.
Second, the Cd24 RNA levels must show a broad distribution.
Three cohorts, including low-grade glioma, glioblastoma and
prostate cancer, satisﬁed both criteria. We divided the
cancer samples into CD24hi (with CD24 mRNA above the
median) and CD24lo (with CD24 mRNA below the median) and
compared the mutation rates. As shown in Fig. 10c, in all three
cancer types, we observed a signiﬁcantly higher rate of TP53
mutation among the CD24hi groups. Based on odds ratio, the
mutations TP53 were two to four times more likely to occur in
CD24hi group. The association was not due to leukocyte
inﬁltration as the RNA for CD45, a pan-leukocyte marker, did
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Figure 9 | CD24 is required for viral oncogene-mediated inactivation of p53 function. (a) By increasing the overall levels of p53 protein, Cd24 silencing
increases the proportion of SV40 T antigen-unbound p53. SV40 T antigen was tagged with Flag and introduced into the mouse prostate cancer cell line C3
with or without transduction of CD24 shRNA. The total cellular (left panel) or SV40 T antigen-associated or non-associated p53 (right panel) were
determined by either western blot or anti-Flag immunoprecipitation followed by western blot. Note that CD24 was not co-precipitated. S: supernatant;
P: pellet. (b) Cd24 silencing reveals p53 function in SV40 large T antigen (SV40 Tag)-transduced (top) and human papilloma viral protein E6 (HPV E6)transduced C3 cells (bottom). SV40 Tag- or HPV E6-transduced C3 cells were transfected with WT or p53-binding site mutant p21 promoter linked with a
luciferase reporter. The function of the endogenous Cd24 and Tp53 locus was conﬁrmed by shRNA silencing of either genes. Data shown are means and s.d.
of relative luciferase activity. (c) In the Tp53 þ / þ TRAMP model, targeted mutation of Cd24 increased the levels of p53 and p21. Data shown are
photographs of immunohistochemical analysis of p21 and p53 levels from either Cd24 þ / þ or Cd24  /  prostate cancer samples. (d) Cd24 silencing
increases the proportion of HPV E6-unbound p53, as in a, except that HPV E6 was used instead of SV40 TAg. All data in this ﬁgure have been reproduced
two or three times. Co-IP, co-immunoprecipitation; Mut, mutant; WB, western blot.

not correlate with either CD24 levels or TP53 mutation rate
(Supplementary Fig. 9).
Discussion
A recent meta-analysis of immunohistochemistry data between
1990 and 2009 revealed that CD24 is expressed in 68% of clinical
samples across all major cancer types62. A major challenge in
understanding the oncogenic function of CD24 is to establish a
central programme determining how CD24 promotes
oncogenesis. Our data reveal a critical role for intracellular
CD24 in tumour cell growth. A mass spectrometry-based
approach led to the identiﬁcation of a CD24–NPM interaction.
This interaction occurred endogenously was direct as it was
recapitulated with recombinant CD24-Fc and NPM–GST fusion
proteins. Interestingly, the association between CD24 and NPM
was most prominent during metaphase and anaphase of mitosis.
As such, it is intriguing to consider whether CD24 function may
be more prominent during mitosis.
In vitro analysis with recombinant CD24, ARF and NPM
provided deﬁnitive evidence that CD24 prevents ARF from
interacting with NPM. Being largely unstructured, ARF is known
to be rapidly degraded unless associated with NPM63. The idea

that CD24 promotes tumour growth by causing ARF degradation
is supported by the fact that ectopic expression of CD24 bypassed
ARF-mediated suppression of growth of cancer cells. CD24 had
no impact on the growth rate in ARF-deﬁcient U2OS cells,
further supporting the concept that CD24 transforming potential
is mediated through ARF. Therefore, a central function of CD24
in cancer cells may be to inhibit the ARF–NPM interaction,
thereby causing ARF degradation. This degradation results in
increased MDM2 levels that subsequently reduced p53 levels.
Although immunoﬂuorescence staining suggests that the
CD24–NPM association was most prominent at M phase,
dispersion of NPM and increased expression of CD24 may have
facilitated observation of CD24–NPM co-localization during
mitosis. A modest but clear co-localization can be found in
non-mitotic cells. Consistent with this notion, we observed
localization of CD24 in the nucleoli (Supplementary Fig. 10).
Therefore, in fact, the association between CD24 and NPM can be
easily detected by co-immunoprecipitation in cells that have
exited from mitosis. Consistent with this view, the impact of
CD24 silencing on NPM-associated ARF was clearly demonstrable among mostly non-mitotic thymocytes. In addition,
proximity ligation assay revealed that CD24 silencing increased
the NPM–ARF association in non-mitotic DU145 cells.
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Furthermore, silencing CD24 increased ARF, p21 and p53 while
reducing MDM2 in non-synchronized DU145 cells.
Oncogenic insults often leads to activation of ataxia telangiectasia mutated (ATM)64. As ATM activation has been shown to be
associated with reduced ARF–NPM association65, it is of interest
to determine whether CD24 activates ATM. As shown in
Supplementary Fig. 11, using p-Ser1981-speciﬁc antibodies as
indicator for ATM activation, we found no evidence of increased
ATM activation in the CD24-expressing DU145 cells.
Previous studies indicate that many of the TP53 mutants,
including nearly 50% of the p53 mutations in glioblastoma, are
temperature sensitive44. Here, we showed that in DU145 cells,
which harbour such a temperature-sensitive mutation, shRNA
silencing of CD24 prevented mutational inactivation of TP53. In
addition, CD24 silencing at least partially restored transcriptional
activity of three out of four cancer-associated p53 mutants,
including the most common R273H mutation. These data
12

support the idea that although not all cancer samples require
CD24 for genetic inactivation of p53, CD24 is a major necessary
cellular component associated with many inactivating p53
mutations in cancer. Furthering this concept, we observed that
in cancers with heterogeneity in CD24 transcripts, the TP53
mutation rate was signiﬁcantly higher among those samples with
higher levels of CD24 transcripts. In addition, our data revealed
that by regulating p53 levels, CD24 also determines the
susceptibility of p53 to inactivation by viral oncogenes, such as
the SV40 large T Ag and HPV16 E6-antigen. Therefore, by
decreasing p53 protein levels, CD24 allows inactivation of p53
activity by both mutation and viral oncogenes.
It should be noted that since ARF is known to suppress tumour
development even in the Tp53  /  mice, it is anticipated that
CD24, being a regulator of ARF degradation, should also function
in a p53-independent manner. Although the mechanism of p53independent pro-tumorigenic actions of CD24 remains to be
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determined, our data support this idea by showing that CD24
silencing also suppresses the growth of p53-null PC3 cells.
Based on the data presented, we propose a mechanism by
which intracellular CD24 regulates cancer pathogenesis. By
inhibiting ARF binding to NPM, intracellular CD24 causes ARF
destabilization that subsequently increases in MDM2 and
decreases p53 and p21. Our model provides a convergent
explanation for three mysteries in cancer pathogenesis: the broad
upregulation of CD24, the predominance of TP53 missense
mutations and the apparent lack of ARF-speciﬁc mutations2,37.
Additional studies in more tumour models will be needed to
determine whether the concept is generally applicable.
Finally, as p53 is among the most commonly inactivated
tumour suppressors, a major challenge in tumour therapy is how
to restore p53 tumour-suppressor activity. In this context, we
showed that in addition to the endogenously expressed
temperature-sensitive mutant in DU145 cells, silencing CD24
also restores at least part of the tumour-suppressor activity of
three out of four p53 mutants, including the most commonly
observed p53R273H mutant. Our data provide a potential
approach to restore p53 function in cancer.
Methods
Experimental animals. Male TRAMP mice in the C57BL/6 background were
purchased from the Jackson Laboratory. The mice were bred at the animal facilities
of the University of Michigan (Ann Arbor, MI, USA). Cd24-deﬁcient C57BL/6
mice have been described previously45. Male BALB/c athymic nude or NSG mice
were purchased from Charles River Laboratories. The progression of prostate
cancer in the TRAMP model was measured by MRI as described previously66. The
pathological evaluation was performed according to the Bar Harbor meeting
guidelines67. All animal experiments were conducted in accordance with accepted
standards of animal care and approved by the Institutional Animal Care and Use
Committee of Children’s Research Institute at Children’s National Medical Center
and the University of Michigan.
Cell lines, antibodies and shRNAs. Prostate cancer cell lines DU145, PC3 and
LNCaP were obtained from the American Type Culture Collection. Antibodies
speciﬁc for the following targets were used for this study: human CD24 (BD
Pharmingen, ML5, Cat #:555426), mouse Cd24 (BD Pharmingen, M1/69, Cat #:
562360), CD24 (Santa Cruz Biotechnology, Cat #: sc-11406 and Cat #: sc-53660,
and SN3b), NPM1 (Abcam, Cat #: ab10530), p14 (Santa Cruz Biotechnology, Cat #:
sc-8340; Cell Signaling, Cat #:2407), p53 (Santa Cruz Biotechnology, DO-1, Cat #:
sc-126; FL-393, Cat #sc-6243), MDM2 (Santa Cruz Biotechnology, Cat #: sc-7918),
p21 (Cell Signaling, Cat #: 2946), p27 (Cell Signaling, Cat #: 2946), Cyclin B1
(Santa Cruz Biotechnology, Cat #: H-433), GFP (Cell Signaling, Cat #: 2946),
Lamin B1 (Santa Cruz Biotechnology, sc-56145), H1.5 (Abcam ab18208), b-actin
(Sigma-Aldrich, Cat #: A5441) and anti-IgG (Santa Cruz Biotechnology), phosphoATM (Ser1981) (Rabbit mAb D6H9, Cat #5883, Cell Signaling) and ATM (Rabbit
mAb D2E2, Cell Signaling, Cat #2873).
The two CD24 shRNA constructs were CD24-V2LHS_71908 (Open
Biosystems, Cat #: RHS4430-99291677, GenBank accession #: NM_013230) and
CD24-V2LHS_71909 (Open Biosystems, Cat #: RHS4430-98854299, GenBank
accession #: L33930). DU145 and PC3 cells were infected with lentivirus expressing
either control shRNA or CD24 shRNA vectors. The sequence of shRNA and
primers used for PCR are listed in Supplementary Table 3.
Fluorescence microscopy. Rabbit anti-NPM (Cat#: sc-6013R, Santa Cruz Biotechnology), mouse anti-CD24 (ML5), mouse anti-a-tubulin, mouse anti-g-tubulin
(Sigma-Aldrich) and rat anti–a-tubulin (Chemicon) were used for immunoﬂuorescence. The binding of antibodies to cells was visualized with secondary
antibodies from Life Technologies: Alexa Fluor 568 Goat Anti-Mouse IgG (H þ L)
Antibody, highly cross-adsorbed (Red), Catalogue Number A-11031 and Alexa
Fluor 488 Goat Anti-Rabbit IgG (H þ L) Antibody, highly cross-adsorbed (Green),
Catalogue Number A-11034. All images were obtained on an inverted microscope
(Axiovert 100 M; Carl Zeiss MicroImaging, Inc.) with an LSM 510 Meta laserscanning confocal module (Carl Zeiss MicroImaging, Inc.). Samples were scanned
with appropriate lasers and ﬁlter sets and images were collected at 0.5 mm intervals
using a  63 water objective (C-Apochromat with 1.2 numerical aperture). LSM
510 Meta software (Carl Zeiss MicroImaging, Inc.) was used to collect images.
Images were analysed with LSM image browser (Carl Zeiss MicroImaging, Inc.).
Gene expression proﬁling and pathway analysis. DU145 cells stably transduced
with lentivirus expressing either control shRNA or CD24 shRNA were seeded onto
10-cm plates and cultured with puromycin. Individual clones were isolated and

tested for CD24 expression. Clones with stable CD24 silencing were used for gene
expression analysis, usually 2 months after the initial transduction. The stable clones
were seeded again in 10-cm plates and at 3–5 days after culture, when the cells
reached 50% conﬂuency, the cells were washed with ice-cold PBS twice and RNA
extraction was performed with the RNeasy Mini kit (Qiagen) according to the
manufacturer’s protocol. Contaminated genomic DNA was eliminated with DNase I
(Invitrogen) according to the manufacturer’s protocol. We conducted mRNA
microarray analysis using HG-U133 Plus 2.0 (Affymeatrix) was performed according
to the manufacturer’s protocol. The microarray data are submitted to NCBI GEO
(accession No. GSE46708). dChip software (University of California at Los Angeles
Clinical Microarray Core) was used to generate a heat map of the microarray proﬁle.
Gene expression proﬁles of cells were compared with and without CD24. Differences
in mRNA expression levels between CD24 þ and CD24  cells were calculated by
Student’s t-test. Ingenuity pathways analysis (IPA) for CD24-related genes was
performed using IPA software (version 7.1, Ingenuity Systems, Inc.).
Co-immunoprecipitation and western blot. Collected cells were washed with
cold PBS and lysed in ice-cold buffer (20 mM Tris–HCl (pH 8.0), 150 mM NaCl,
1 mM EDTA, 1% NP-40) supplemented with complete protease inhibitors (SigmaAldrich) on ice for 10 min. The samples were centrifuged at 13,000 r.p.m. for
10 min. The lysates were aliquoted into two tubes and incubated with either the
designated antibody or an appropriate IgG control for 16 h at 4 °C. Protein A/G
agarose (Invitrogen) was used to precipitate antibody–protein complexes.
For western blotting, anti-CD24 (Santa Cruz Biotechnology, 1:1,000), anti-p27
(Cell Signaling, 1:1,000), anti-p21 (Cell Signaling, 1:1,000), anti-p53 (Santa Cruz
Biotechnology, 1:2,000), anti-Lamin (Santa Cruz Biotechnology, 1:5,000), anti-H1.5
(Abcam, 1:5,000), anti-Cyclin B1 (Santa Cruz Biotechnology, 1:3,000), anti-GFP
(Cell Signaling, 1:2,000), anti-NPM1 (Abcam, 1:3,000), anti-HA (Sigma-Aldrich,
1:3,000), anti-Myc (Abcam, 1:3,000), anti-ARF (Santa Cruz Biotechnology,
1:1,000), anti-MDM2 (Santa Cruz Biotechnology, 1:1,000) and anti-b-actin
(Sigma, 1:5,000) antibodies were used as primary antibodies. The membranes were
incubated for 1 h at room temperature in 0.25% nonfat milk with a 1:3,000–5,000
dilution of either anti-rabbit or anti-mouse IgG HRP-linked secondary antibody
(Cell Signaling).
Colony formation assay. The colony formation assay was carried out as we have
described previously68. DU145 or PC3 cells were transfected with either the control
vector or vectors (CD24 shRNAs, CD24-EGFP-N, CD24-EGFP-C). At 48 h after
transfection, cells were counted and 4  104 transfected cells were plated in
100-mm dishes in triplicate and cultured in medium containing 10 mg ml  1
puromycin. After 3 weeks in culture, the colonies were stained with 0.125% crystal
violet. The colonies were either photographed or counted. The total number of
colonies (Z20 cells) per plate was counted using a microscope.
Xenogeneic transplantation. DU145 and PC3 cells transduced with scrambled or
with CD24 shRNA, or cDNA for CD24-EGFP (C), and CD24-EGFP (N) fusion
proteins were grown in Eagle’s Minimum Essential Media supplemented with 10%
fetal bovine serum without antibiotics. Cells were expanded and used for inoculation within three to four passages after thawing from liquid nitrogen storage.
Male BALB/c athymic nude mice were obtained from Charles River Laboratories,
whereas NSG mice were purchased from the Jackson Laboratories. Eight-week-old
SCID mice (Jackson Laboratories) were used as recipients that received subcutaneous injections on the left ﬂank of 100 ml containing 5  106 cells DU145 cells.
Tumour size was measured using a Vernier caliper in the two longest dimensions.
Tumour volume was calculated with the following formula 0.5D1(D2)2, where D1
is the long measure and D2 is the short dimension. The experiments were terminated when the xenograft tumour size in the control group reached a group
average calculated volume of 1  103 mm3.
Flow cytometry. For cell surface staining, cells were incubated with antibodies in
staining buffer for 30 min on ice. Cells were then washed three times and ﬁxed. For
intracellular staining, cells were ﬁrst ﬁxed with Cytoﬁx/Cytoperm buffer (BD
Biosciences), followed by washing with Perm/Wash buffer (BD Biosciences), and
incubated with anti-CD24 in Perm/Wash buffer for 30 min on ice. For the staining
of intracellular CD24, viable cells were ﬁrst ﬁxed in the Cytoﬁx/Cytoperm buffer
followed by staining with PE-labelled anti-CD24 antibody and isotype control in
Perm/Wash buffer. Cells were analysed on an LSII cytometer (Becton Dickinson).
For cell cycle progression, the cell monolayer was harvested after treatment with
EDTA-trypsin, washed with ice-cold PBS and ﬁxed in ice-cold 70% ethanol
overnight at  20 °C. After washing twice with PBS, the cells were incubated in
RNase A-PBS (100 mg ml  1) at 37 °C for 30 min. DNA was labelled with
propidium iodide (50 mg ml  1; BD Biosciences) and analysed with an LSII ﬂow
cytometer and CELLQuest software (Becton Dickinson). The percentage of cells in
G0/G1, S and G2/M phases was evaluated by analysing 2  104 cells using the
ModFit LT 3.0 program (Becton Dickinson).
Immunohistochemistry. Normal and prostate cancer frozen samples were partially thawed at room temperature and then immersed in 10% formalin for 12 h at
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8 °C and embedded in parafﬁn. Antigens were retrieved by microwaving in
retrieval buffer (Dako) for 12 min. The ABC detection system was used for
immunostaining according to the manufacturer’s protocol (Vectastain Elite ABC).
The primary antibodies were incubated with tissues overnight at 4 °C. This incubation was followed by the ABC detection system using biotinylated anti-mouse/
rabbit/rat IgG. The slides were counterstained with haematoxylin and mounted in
xylene mounting medium for examination.
Proximity ligation assay. We conducted proximity ligation assays using Duolink
In Situ Red Starter Kit Mouse/Rabbit (Cat#: DUO92101, Sigma-Aldrich) according
to the manufacturer’s protocol. Du145 cells stabilized with lentivirus expressing
either control shRNA or CD24 shRNA were seeded in chamber slides (Nunc LabTek) and ﬁxed with 4% paraformaldehyde. Rabbit anti-NPM (Cat#: sc-6013R,
Santa Cruz Biotechnology, 1:100) and mouse anti-p14ARF (Cat#: 2407, Cell
Signaling, 1:100) were used as primary antibodies.
In silico analysis of CD24 expression and TP53 status. CD24 expression data
(RNA Seq) and TP53 mutation status for low-grade glioma, glioblastoma and
prostate adenocarcinoma were obtained from the Memorial Sloan Kettering
Cancer Genomics Portal 74,75 (http://www.cbioportal.org/public-portal; last
accessed on 25 April 2014). A function was implemented in the R software (http://
www.r-project.org) to make the distribution diagrams that depict RNAseq values
for CD24 and CD45 among samples with WT or mutant TP53. The samples from a
given cancer cohort were divided into CD24hi or CD24lo subcohorts based on
whether the RNAseq reads were above or below the mean of the cohort. The
Pearson’s w2 test was used to evaluate the statistical signiﬁcance in the frequencies
of TP53 mutation in the CD24hi and CD24lo subcohorts.
Statistics. The log-rank test was used for survival analysis, Student’s t-test was
used for pairwise comparison, whereas Pearson’s w2 test was used for multiple
group comparisons. The analysis of variance trend test was used for gene dosage
effect. Tumour growth rates were compared by Fisher’s Least Signiﬁcant Difference
test. Unless speciﬁc P-values are provided, those that reached statistical signiﬁcance
are given as follows: *Po0.05; **Po0.01; ***Po0.001.
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